AnaptysBio Inc (NASDAQ:ANAB) has received an average recommendation of “Buy” from the ten analysts that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $136.63.
Several research analysts have issued reports on the stock. Royal Bank of Canada raised their price target on shares of AnaptysBio to $144.00 and gave the stock an “outperform” rating in a report on Friday, March 2nd. Wedbush restated an “outperform” rating and set a $142.00 price target on shares of AnaptysBio in a report on Tuesday, February 20th. Jefferies Group raised their price target on shares of AnaptysBio from $6.59 to $145.00 and gave the stock a “buy” rating in a report on Monday, February 19th. SunTrust Banks raised their price target on shares of AnaptysBio from $115.00 to $162.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Finally, Stifel Nicolaus raised their price target on shares of AnaptysBio from $130.00 to $139.00 and gave the stock a “buy” rating in a report on Tuesday, March 6th.
AnaptysBio (NASDAQ ANAB) traded down $4.64 during trading on Friday, reaching $110.13. 206,934 shares of the company’s stock traded hands, compared to its average volume of 295,134. The company has a current ratio of 17.93, a quick ratio of 17.93 and a debt-to-equity ratio of 0.02. AnaptysBio has a 52-week low of $18.15 and a 52-week high of $134.00. The company has a market cap of $2,707.90, a price-to-earnings ratio of -67.56 and a beta of 1.94.
AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, March 5th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.12. The firm had revenue of $3.00 million for the quarter, compared to the consensus estimate of $0.89 million. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. equities research analysts expect that AnaptysBio will post -2.3 EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the company. Evercore Wealth Management LLC bought a new stake in shares of AnaptysBio in the 3rd quarter valued at $100,000. Legal & General Group Plc increased its stake in shares of AnaptysBio by 160.8% in the 3rd quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock valued at $110,000 after acquiring an additional 1,951 shares in the last quarter. New York State Common Retirement Fund bought a new stake in shares of AnaptysBio in the 2nd quarter valued at $168,000. Nationwide Fund Advisors increased its stake in shares of AnaptysBio by 89.5% in the 3rd quarter. Nationwide Fund Advisors now owns 5,878 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 2,776 shares in the last quarter. Finally, Two Sigma Securities LLC bought a new stake in shares of AnaptysBio in the 4th quarter valued at $212,000. Institutional investors own 99.25% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “AnaptysBio Inc (ANAB) Receives $136.63 Average PT from Analysts” was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.thelincolnianonline.com/2018/03/22/anaptysbio-inc-anab-receives-136-63-average-pt-from-analysts.html.
AnaptysBio, Inc is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.